Search

everythinglearnresearchcommunity

for

Search:↓

The immune processes causing VKH and vitiligo are similar in dogs and humans.

Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

JAK inhibitors might help treat alopecia areata.

JAK inhibitors show promise for treating various skin diseases.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

Janus Kinase Inhibitors are promising new treatments for various skin conditions due to their effectiveness and safety.

New treatments for severe alopecia areata show promise but lack standard approval.

Baricitinib may help treat frontal fibrosing alopecia and facial papules.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

JAK inhibitors show promise in treating difficult skin diseases.

Interleukin-1 increases keratin K6 production in skin cells.

Blocking JAK-STAT signaling can lead to hair growth.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Baricitinib is effective and safe for treating severe alopecia areata.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Type I interferons play a key role in the development of various skin diseases.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.

Upadacitinib may cause hair loss.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.